Affordable Access

Access to the full text

Technical feasibility of [18F]FET and [18F]FAZA PET guided radiotherapy in a F98 glioblastoma rat model

Authors
  • Verhoeven, Jeroen1
  • Bolcaen, Julie2, 3
  • De Meulenaere, Valerie4
  • Kersemans, Ken2
  • Descamps, Benedicte5
  • Donche, Sam2
  • Van den Broecke, Caroline6
  • Boterberg, Tom7
  • Kalala, Jean-Pierre8
  • Deblaere, Karel4
  • Vanhove, Christian5
  • De Vos, Filip1
  • Goethals, Ingeborg2
  • 1 Ghent University, Laboratory of Radiopharmacy, Ghent, Belgium , Ghent (Belgium)
  • 2 Ghent University Hospital, Department of Nuclear Medicine, Ghent, Belgium , Ghent (Belgium)
  • 3 National Research Foundation (NRF), iThemba LABS, Somerset West, South Africa , Somerset West (South Africa)
  • 4 Ghent University Hospital, Department of Radiology and Medical Imaging, Ghent, Belgium , Ghent (Belgium)
  • 5 IBiTech-MEDISIP Ghent University, Department of Electronics and Information Systems, Ghent, Belgium , Ghent (Belgium)
  • 6 Ghent University Hospital, Department of Pathology, Ghent, Belgium , Ghent (Belgium)
  • 7 Ghent University Hospital, Department of Radiation Oncology, Ghent, Belgium , Ghent (Belgium)
  • 8 Ghent University Hospital, Department of Neurosurgery, Ghent, Belgium , Ghent (Belgium)
Type
Published Article
Journal
Radiation Oncology
Publisher
Springer (Biomed Central Ltd.)
Publication Date
May 30, 2019
Volume
14
Issue
1
Identifiers
DOI: 10.1186/s13014-019-1290-4
Source
Springer Nature
Keywords
License
Green

Abstract

BackgroundGlioblastoma (GB) is the most common primary malignant brain tumor. Standard medical treatment consists of a maximal safe surgical resection, subsequently radiation therapy (RT) and chemotherapy with temozolomide (TMZ). An accurate definition of the tumor volume is of utmost importance for guiding RT. In this project we investigated the feasibility and treatment response of subvolume boosting to a PET-defined tumor part.MethodF98 GB cells inoculated in the rat brain were imaged using T2- and contrast-enhanced T1-weighted (T1w) MRI. A dose of 20 Gy (5 × 5 mm2) was delivered to the target volume delineated based on T1w MRI for three treatment groups. Two of those treatment groups received an additional radiation boost of 5 Gy (1 × 1 mm2) delivered to the region either with maximum [18F]FET or [18F]FAZA PET tracer uptake, respectively. All therapy groups received intraperitoneal (IP) injections of TMZ. Finally, a control group received no RT and only control IP injections. The average, minimum and maximum dose, as well as the D90-, D50- and D2- values were calculated for nine rats using both RT plans. To evaluate response to therapy, follow-up tumor volumes were delineated based on T1w MRI.ResultsWhen comparing the dose volume histograms, a significant difference was found exclusively between the D2-values. A significant difference in tumor growth was only found between active therapy and sham therapy respectively, while no significant differences were found when comparing the three treatment groups.ConclusionIn this study we showed the feasibility of PET guided subvolume boosting of F98 glioblastoma in rats. No evidence was found for a beneficial effect regarding tumor response. However, improvements for dose targeting in rodents and studies investigating new targeted drugs for GB treatment are mandatory.

Report this publication

Statistics

Seen <100 times